FACTOR XIII V34L POLYMORPHISM IN A POPULATION OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA FROM NORTH-EASTERN ROMANIA
Abstract
Familial hypercholesterolemia (FH) is one of the most frequent inherited genetic disorders of the cholesterol metabolism that has an autosomal dominant or multifactorial inheritance. Factor XIII is also called the factor that stabilizes the fibrin, being an enzyme that makes the bond between the fibrin molecules during the clot formation. The gene for factor XIII is localized on 6p24-25 and can suffer a substitution in 103G>T position (V34L polymorphism), that can decrease the stability of the clot, offering protection for thrombo-embolic events and a decreased risk for myocardial infarction and coronary artery disease. Materials and methods: A cross-sectional study was conducted in the Cardiovascular Rehabilitation Clinic from the Clinical Rehabilitation Hospital from Iasi from 1st December 2020 to 31st of March 2022, included 70 patients diagnosed with certain FH based on the Dutch Lipid Clinical Network score (DLCN) and 20 patients in the control group. Results: The homozygous patients had the highest values of the corrected LDL-C and the heterozygous patients had the lowest total bilirubin concentrations. The patients included in the control group that had the homozygous variant had the lowest total cholesterol and non-HDL concentrations. Conclusions: This approach enables the implementation of targeted management and treatment approaches to effectively mitigate the risks associated with this condition. The costs of genetic testing decrease over time, the significance of this information is likely to increase even further.
References
2. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers 2019; 5(1): 56 / doi: 10.1038/s41572-019-0106-z.
3. Abifadel M, Boileau C. Genetic and molecular architecture of familial hypercholesterolemia. J Intern Med 2023; 293(2): 144-165 / doi: 10.1111/joim.13577.
4. Nohara A, Tada H, Ogura M, et al. Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb 2021; 28(7): 665-678 / doi: 10.5551/jat.RV17050.
5. Zubielienė K, Valterytė G, Jonaitienė N, Žaliaduonytė D, Zabiela V. Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis. Medicina (Kaunas) 2022; 58(11): 1665 / doi: 10.3390/medicina58111665.
6. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205 / doi: 10.1016/j.atherosclerosis.2019.08.014.
7. Banda JM, Sarraju A, Abbasi F, et al. Finding missed cases of familial hypercholesterolemia in health systems using machine learning. NPJ Digit Med 2019; 2: 23 / doi: 10.1038/s41746-019-0101-5.
8. Javed H, Singh S, Ramaraje Urs SU, Oldenburg J, Biswas A. Genetic landscape in coagulation factor XIII associated defects - Advances in coagulation and beyond. Blood Rev 2023; 59: 101032 / doi: 10.1016/j.blre.2022.101032.
9. Alshehri FSM, Whyte CS, Mutch NJ. Factor XIII-A: An Indispensable “Factor” in Haemostasis and Wound Healing. Int J Mol Sci 2021; 22(6): 3055 / doi: 10.3390/ijms2206 3055.
10. Fountoglou N, Petropoulou M, Iliadi A, Christopoulos TK, Ioannou PC. Τwo-panel molecular testing for genetic predisposition for thrombosis using multi-allele visual biosensors. Anal Bioanal Chem 2016; 408(7): 1943-1952 / doi: 10.1007/s00216-016-9310-9.
11. Trumbo TA, Maurer MC. Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P(9) and P(4) positions in factor XIII activation. Biochemistry 2002; 41(8): 2859-2868 / doi: 10.1021/bi0157823.
12. Byrnes JR, Wolberg AS. Newly-Recognized Roles of Factor XIII in Thrombosis. Semin Thromb Hemost 2016; 42(4): 445-454 / doi: 10.1055/s-0036-1571343.
13. Haralambos K, Whatley SD, Edwards R, et al. Clinical experience of scoring criteria for Familial Hypercholesterolemia (FH) genetic testing in Wales. Atherosclerosis 2015; 240(1): 190-196 / doi: 10.1016/j.atherosclerosis.2015.03.003.
14. Phasha MN, Soma P, Bester J, Pretorius E, Phulukdaree A. Factor XIII-A Val34Leu and Tyr204Phe variants influence clot kinetics in a cohort of South African type 2 diabetes mellitus patients. Gene 2022; 834: 146637 / doi: 10.1016/j.gene.2022.146637.
15. Ambroziak M, Kuryłowicz A, Budaj A. Increased coagulation factor XIII activity but not genetic variants of coagulation factors are associated with myocardial infarction in young patients. J Thromb Thrombolysis 2019; 48(3): 519-527 / doi: 10.1007/s11239-019-01856-3.
Additional Files
Published
Issue
Section
License
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
